Kiniksa Pharmaceuticals International, plc
No SEC Form 4 filings for $KNSA in the last 30 days.
See all $KNSA insider activity →Kiniksa Pharmaceuticals (KNSA) appointed Ross Moat as president and COO, effective immediately. His salary will increase to $700,000 and target bonus to 60% from January 1, 2027. Moat has worked at the company since 2019, most recently as EVP and COO.
Kiniksa Pharmaceuticals International, plc (KNSA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 17, 2026, the Compensation Committee (the “Committee”) of the Board of Directors of Kiniksa Pharmaceuticals I
Kiniksa Pharmaceuticals (KNSA) shares fell 4.2% to $79.70. GuruFocus estimates the stock is overvalued by 40.1%, with a GF Value of $56.90. KNSA has a GF Score of 48/100, indicating average performance. Insiders sold $57.9M in shares over the past year. The P/E ratio is 81.0x, higher than its 5-year median of 61.9x.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning KNSA (Kiniksa Pharmaceuticals International, plc). Coverage has skewed bearish: 0 bullish, 2 neutral, and 1 bearish.
Recent KNSA coverage spans earnings, market movers and financial news.
The appointment may signal operational focus but likely has limited immediate price effect.
Executive appointment and salary raise may signal operational focus and could modestly affect stock perception.
The price decline reflects market concern over overvaluation and heavy insider selling.
The guidance hike is a direct fundamental catalyst that can re-rate near-term earnings power, but the article flags ongoing concentration risk around ARCALYST.
This is a routine insider open-market sale with no 10b5-1 plan cited, but it does not disclose company fundamentals.
AlphAI scores every news story that mentions KNSA with an AI model for sentiment and relevance, and aggregates insider trades from Kiniksa Pharmaceuticals International, plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Kiniksa Pharmaceuticals (KNSA) appointed Ross Moat as president and COO, effective immediately. His salary will increase to $700,000 and target bonus to 60% from January 1, 2027. Moat has worked at the company since 2019, most recently as EVP and COO.
1 min readKiniksa Pharmaceuticals International, plc (KNSA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 17, 2026, the Compensation Committee (the “Committee”) of the Board of Directors of Kiniksa Pharmaceuticals I
1 min readKiniksa Pharmaceuticals (KNSA) shares fell 4.2% to $79.70. GuruFocus estimates the stock is overvalued by 40.1%, with a GF Value of $56.90. KNSA has a GF Score of 48/100, indicating average performance. Insiders sold $57.9M in shares over the past year. The P/E ratio is 81.0x, higher than its 5-year median of 61.9x.
2 min readKiniksa Pharmaceuticals International (KNSA) reported Q2 2026 revenue of $243.6 million and net income of $25.43 million. The company raised full-year 2026 net product revenue guidance to $980 million to $995 million from $930 million to $945 million, citing durability of its commercial portfolio and ARCALYST uptake.
6 min readCole G Bradley sold 3,673 shares of Kiniksa Pharmaceuticals International, plc (KNSA) at $81.43 ($0.30M total) on 2026-07-29.
2 min readBiotech gainers included Trinity Biotech (TRIB), which rose 36% after Q2 results and a one-for-thirty reverse ADS split to regain Nasdaq bid compliance. OPKO Health (OPK) gained 33% on Q2 revenue of $163.5M and softer Q3/full-year guidance. Kiniksa (KNSA) jumped 25% after raising 2026 net product revenue outlook to $980M-$995M. MapLight (MPLT) rebounded 24% after mixed Phase 2 schizophrenia data. ProMIS (PMN) rose 24% on interim Alzheimer’s data; Prelude (PRLD) rose 19% without specific news.
7 min readKiniksa Pharmaceuticals (KNSA) reported Q2 2026 results, led by ARCALYST net product revenue of $243.6M, up from $156.8M in Q2 2025. Q2 net income was $25.4M, or $0.30 per diluted share. FY 2026 ARCALYST guidance was raised to $980M-$995M. Pipeline updates include KPL-387 Phase 3 planning and KPL-1161 Phase 1 progress.
5 min readKiniksa Pharmaceuticals International plc shares rose about 21% on Nasdaq after its Q2 results for ARCALYST (rilonacept) beat expectations and it raised 2026 guidance. Net product revenue was $243.6M, about 55% higher year over year. 2026 guidance increased to $980M-$995M from $930M-$945M. Kiniksa also reported Q2 net income of $25.4M and $525.9M cash, and is enrolling PASTORALE for KPL-387.
7 min readKiniksa Pharmaceuticals International, plc (KNSA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 knsa-20260728xex99d1.htm EX-99.1 Exhibit 99.1 Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution – ARCALYST ® (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth –
4 min readBiotech stocks outperformed the broader market this year as investors rotated into growth and as M&A activity picked up, according to a Wedbush interview on BNN Bloomberg. The report cites an $11 billion AbbVie deal for Apogee. Wedbush highlighted Kiniksa (Q revenue $214M; raised guidance), Monte Rosa (Phase 2 updates), and Scholar Rock (FDA PDUFA Sept. 30; revenue estimates $163M in 2027, $450M in 2028).
6 min read
